Valuation
- Market cap
- 27,719,000
- Revenue TTM
- $3,630,000
- Net income TTM
- $-5,100,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- -140.50%
- Debt to equity
- 0.00
Trading
- Volume
- 4,600
- Avg volume
- 28,424
- Day's range
- $0.06 – $0.06
- Shares out
- 513,312,000
- Stochastic %K
- 22%
- Beta
- —
- Analysts
- —
- Price target
- —
Company profile
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2b clinical trial for pancreatic cancer; and treatment of ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis i...
Show more
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2b clinical trial for pancreatic cancer; and treatment of ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 61 3 9123 1140
- Website
- https://www.ampliatx.com
- Address
- 90 William Street, Level 5, Melbourne, Australia
Latest news
No headlines yet.
